MCH ADVISORY RESEARCH
Health Care

Life Sciences Tools & Services

12 companies under coverage.

Coverage

Life Sciences Tools & Services


Equity Research

Waters Corporation (WAT)

SELL. 12-month probability-weighted target $365 (-11% vs spot). P/E Multiple explains 84% of Monte Carlo outcome variance.

WATEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Thermo Fisher Scientific Inc (TMO)

SELL. 12-month probability-weighted target $512 (-19% vs spot). P/E Multiple explains 69% of Monte Carlo outcome variance.

TMOEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Mettler-Toledo International Inc (MTD)

SELL. 12-month probability-weighted target $1246 (-11% vs spot). P/E Multiple explains 72% of Monte Carlo outcome variance.

MTDEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Medpace Holdings Inc (MEDP)

SELL. 12-month probability-weighted target $529 (-15% vs spot). P/E Multiple explains 62% of Monte Carlo outcome variance.

MEDPEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

IQVIA Holdings Inc (IQV)

SELL. 12-month probability-weighted target $189 (-27% vs spot). Gross Margin explains 48% of Monte Carlo outcome variance.

IQVEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Illumina Inc (ILMN)

SELL. 12-month probability-weighted target $187 (-16% vs spot). P/E Multiple explains 63% of Monte Carlo outcome variance.

ILMNEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Danaher Corporation (DHR)

HOLD. 12-month probability-weighted target $194 (-10% vs spot). P/E Multiple explains 73% of Monte Carlo outcome variance.

DHREquity ResearchMonte Carlo
25 August 2026Rating: HOLD
Equity Research

Charles River Laboratories (CRL)

SELL. 12-month probability-weighted target $209 (-30% vs spot). P/E Multiple explains 49% of Monte Carlo outcome variance.

CRLEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Bio-Rad Laboratories Inc (BIO)

SELL. 12-month probability-weighted target $299 (-22% vs spot). Gross Margin explains 64% of Monte Carlo outcome variance.

BIOEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Avantor Inc (AVTR)

SELL. 12-month probability-weighted target $11 (-25% vs spot). Gross Margin explains 64% of Monte Carlo outcome variance.

AVTREquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Agilent Technologies Inc (A)

SELL. 12-month probability-weighted target $133 (-13% vs spot). P/E Multiple explains 72% of Monte Carlo outcome variance.

AEquity ResearchMonte Carlo
25 August 2026Rating: SELL
Equity Research

Bio-Techne Corp (TECH)

At roughly $71, on the engine's base earnings near $2.01 the stock trades close to a mid-thirties forward multiple. That price says the market expects biopharma R&D and bioprocessing demand to normalise to…

TECHEquity ResearchMonte Carlo
30 July 2026Rating: N/A
MCH ADVISORY SERVICES · All research · Not investment advicemchadvisoryservices.com ↗ · Research Standard v4 (decision-level) · Research OS ros-1.19.0 · US-listed · UK English